SEC Filing: Form 10-Q
Quarterly report [Sections 13 or 15(d)]
Quarterly report [Sections 13 or 15(d)]
VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and nine months ended September 30, 2022.
Current report
Current report